Schedule Update - effective 1 April 2009 (text extract)

This is the text extract for Schedule Update - effective 1 April 2009, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 April 2009 Cumulative for January, February, March and April 2009 Section H for April 2009

Contents

Summary of PHARMAC decisions effective 1 April 2009 ............................... 3 Atomoxetine hydrochloride – new listing for attention deficit and hyperactivity disorder .................................................................................... 4 Sole Subsidised Supply .................................................................................. 5 Looking Forward ........................................................................................... 5 Sole Subsidised Supply products cumulative to April 2009 ........................... 6 New Listings ................................................................................................ 15 Changes to Restrictions ............................................................................... 18 Changes to Subsidy and Manufacturer’s Price............................................. 27 Changes to Brand Name ............................................................................. 34 Changes to Description ............................................................................... 35 Changes to General Rules............................................................................ 36 Changes to PSO........................................................................................... 36 Changes to Sole Subsidised Supply ............................................................. 36 Delisted Items ............................................................................................. 37 Items to be Delisted .................................................................................... 39 Section H changes to Part II ........................................................................ 43 Index ........................................................................................................... 45

Summary of PharmaC decisions

effeCtIve 1 aPrIL 2009 New listings (page 15) • Apomorphine hydrochloride (Apomine) inj 10 mg per ml, 2 ml • Atomoxetine (Strattera) cap 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg – Special Authority – Retail Pharmacy • Clozapine (Clozaril) tab 25 mg and 100 mg • Danazol (Azol) cap 100 mg – Retail pharmacy-Specialist • Ropirinole hydrochloride (Ropin) tab 0.25 mg, 1 mg, 2 mg and 5 mg • Food thickener (Resource Thicken Up) powder 6 kg – Special Authority – Retail pharmacy • Gemcitabine hydrochloride (Gemcitabine Ebewe) inj 200 mg and 1 g Changes to restrictions (pages 18 – 21) • Acitretin(Neotigason) cap 10 mg and 25 mg - amended Special Authority criteria • Isotretinoin (Isotane) cap 10 mg and 25 mg - amended Special Authority criteria • Ondansetron (Zofran) tab 4 mg and 8 mg and (Zofran Zydis) tab disp 4 mg and 8 mg – addition of Access Exemption Criteria restriction • Pegylated interferon alpha-2a (Pegasys) inj 135 μg and 180 μg prefilled syringe – amended Special Authority criteria • Pegylated interferon alpha-2a (Pegasys RBV Combination pack) inj 135 μg prefilled syringe × 4 with ribavirin tab 200 mg – amended Special Authority criteria • Pegylated interferon alpha-2a (Pegasys RBV Combination Pack) inj 180 μg pre-filled syringe × 4 with ribavirin tab 200 mg – amended Special Authority criteria • Pegylated interferon alpha-2b (Pegatron Combination Therapy) inj 50 μg, 80 μg, 100 μg, 120 μg and 150 μg prefilled syringe with ribavirin tab – amended Special Authority criteria • Ropinirole hydrochloride (Requip and Ropin) – removal of Retail pharmacySpecialist Decreased subsidy (pages 26 – 27) • Acitretin (Neotigason) cap 10 mg and 25 mg • Bezafibrate (Bezalip Retard) tab long-acting 400 mg • Diazepam (Stesolid) rectal tubes 5 mg and 10 mg • Insulin aspart (Novorapid Penfill) inj 100 u per ml, 3 ml • Insulin aspart (Novorapid) inj 100 u per ml, 10 ml Increased subsidy (pages 26 – 27) • Ethambutol hydrochloride (Myambutol • Trifluoperazine (Stelazine

S29 S29

) tab 400 mg

• Paracetamol (Panadol) suppos 125 mg and 250 mg ) tab 1 mg, 2 mg and 5 mg

Pharmaceutical Schedule - Update News

Atomoxetine hydrochloride – new listing for attention deficit and hyperactivity disorder

From 1 April 2009 atomoxetine hydrochloride (Strattera) will be funded for people with attention deficit and hyperactivity disorder (ADHD). Atomoxetine will be available under Special Authority restrictions for people who have not responded to, have experienced side effects from, or are unable to take, methylphenidate and dexamphetamine. Special Authority approvals for other ADHD treatments will not be interchangeable

with the Special Authority for atomoxetine hydrochloride. Various strengths of atomoxetine hydrochloride capsules will be subsidised, ranging from 10 mg to 100 mg. See page 15 for details.

Sole Subsidised Supply

Sole Subsidised Supply changes – effective 1 May 2009

Chemical Name Amlodipine Cetrizine hydrochloride Cetrizine hydrochloride Paracetamol Presentation; Pack size Tab 5 mg and 10 mg Tab 10 mg Oral liq 1 mg per ml; 200 ml Tab 500 mg; 1,000 Sole Subsidised Supply brand (and supplier) Apo-Amlodipine (Apotex NZ Ltd) Zetop (Arrow Pharmaceuticals) Cetrizine-AFT (AFT Pharmaceuticals) Pharmacare Paracetamol (API Consumer Brands)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule. Possible decisions for implementation 1 may 2009 •Dextropropoxyphene with paracetamol (Paramax and Capadex) – subsidy reduction to the level of paracetamol tab 500 mg

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Acetazolamide Aciclovir Alprazolam

Presentation

Tab 250 mg; 100 tab Tab dispersible 200 mg Tab dispersible 400 mg Tab 250 µg Tab 500 µg Tab 1 mg Inj 10 mg per ml, 1 ml Cap 100 mg Drops 100 mg per ml; 30 ml OP Inj 250 mg; 10 pack Inj 500 mg; 10 pack Inj 1 g; 10 pack Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Crm 500 g; pot Tab 100 mg Tab dispersible 300 mg Tab 100 mg Tab 50 mg & 100 mg Eye drops 1%; 15 ml OP Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Tab 500 mg Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg Inj 1 mega u; 10 inj Scalp app 0.1% Tab 200 mg; 90 tab Tab 50 mg Tab 5 mg Eye drops 0.2% Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Lotion BP Crm, aqueous, BP Inj 100 iu per ml, 1 ml; 5 inj Cap 0.25 µg & 0.5 µg Tab eff 1 g; 30 tab Inj 50 mg

Brand Name Expiry Date*

Diamox Lovir Lovir Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam Mayne Symmetrel Ospamox Ibiamox Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin AFT Apo-Ascorbic Acid Ethics Aspirin Ethics Aspirin EC Loten Atropt AstraZeneca AstraZeneca Arrow-Azithromycin Alanase Alanase Sandoz Beta Scalp Fibalip Bicalox Lax-Tab AFT Marcain Isobaric Marcain Heavy ABM ABM Miacalcic Calcitriol-AFT Calsource Calcium Folinate Ebewe 2009 2010 2009 2011 2009 2009 2009 2011 2009 2011 2011 2010 2011 2010 2009 2011 2009 2011 2011 2011 2009 2010

Apomorphine hydrochloride Amantadine hydrochloride Amoxycillin

2009 2011 2011

2010 2009

Aqueous cream Ascorbic acid Aspirin Atenolol Atropine sulphate

Azithromycin Beclomethasone dipropionate Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Bezafibrate Bicalutamide Bisacodyl Brimonidine tartrate Bupivicaine hydrochloride Calamine Calcitonin Calcitriol Calcium Calcium folinate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 6

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Captopril Cefaclor monohydrate Cefazolin sodium Cefuroxime sodium Cetomacrogol Chloramphenicol Chlorhexidine gluconate

Presentation

Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Inj 500 mg Inj 1 g Inj 750 mg & 1.5 g Crm BP Eye drops 0.5% Eye oint 1% Soln 4% Handrub 1% with ethanol 70% Mouthwash 0.2% Tab 25 mg Tab 250 mg Tab 500 mg Tab 750 mg Tab 20 mg; 84 pack Tab 250 mg Grans for oral liq 125 mg per 5 ml Crm 0.05% Tab 500 µg; 100 tab Tab 2 mg; 100 tab Vaginal crm 2%; 20 g OP Crm 1% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg Cap 25 mg & 50 mg Inj 500 mg Nasal spray 10 mcg per dose Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Tab 5 mg

Brand Name Expiry Date*

Apo-Captopril Ranbaxy Cefaclor Ranbaxy Cefaclor Hospira Zinacef PSM Chlorsig Chlorsig Orion Orion Orion Hygroton Rex Medical 2010 2010 2011 2011 2010 2009 2011 2009 2009 2011

Chlorthalidone Ciprofloxacin

Citalopram Clarithromycin Clobetasol propionate Clonazepam Clotrimazole

Arrow-Citalopram Klamycin Klacid Dermol Paxam Paxam Clomazol Clomazol Clomazol PSM Colgout Colestid Colistin-Link Enerlyte Nausicalm Cycloblastin Siterone Dantrium Mayne Desmopressin-PH&T Mayne PSM

2010 2010 2009 2011 2010

Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Dantrolene sodium Desferrioxamine mesylate Desmopressin Dexamethasone sodium phosphate Dexamphetamine sulphate

2010 2010 2010 2010 2010 2009 2010 2009 2009 2010 2011 2009 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 7

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Dextrose Dextrose with electrolytes

Presentation

Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Voltaren Ophtha Voltaren Voltaren Voltaren Voltaren Voltaren Apo-Diclo Apo-Diclo SR Videx EC Pytazen SR Apo-Doxazosin AFT m-Enalapril Mayne Cafergot E-Mycin E-Mycin New Zealand Medical and Scientific Brevinor 21 Brevinor 1/21 Brevinor 1/28 Vepesid Ferodan Fintral Flucloxin 2009 2010 2011 2011 2009 2010 2011 2010

Diclofenac sodium

Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg Suppos 25 mg Suppos 50 mg Suppos 100 mg Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Cap 125 mg, 200 mg, 250 mg & 400 mg Tab long-acting 150 mg Tab 2 mg & 4 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 500 µg per ml, 1 ml Tab 1 mg with caffeine 100 mg Grans for oral liq 200 mg per 5 ml; 100 ml Grans for oral liq 400 mg per 5 ml; 100 ml Tab 10 µg Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Cap 50 mg & 100 mg Oral liq 150 mg per 5 ml Tab 5 mg; 30 tab Inj 250 mg; 10 pack Inj 500 mg; 10 pack Inj 1 g; 10 pack Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 50 mg Cap 150 mg Cap 200 mg

2011

2009 2009 2011 2010 2011 2009 2009 2009 2011

Didanosine (DDI) Dipyridamole Doxazosin mesylate Emulsifying ointment Enalapril Ergometrine maleate Ergotamine tartrate with caffeine Erythromycin ethyl succinate

Ethinyloestradiol Ethinyloestradiol with norethisterone

Etoposide Ferrous sulphate Finasteride Flucloxacillin

Flucloxacillin sodium

Staphlex AFT AFT Pacific Pacific Pacific

2009

Fluconazole

2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 8

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Fludarabine phosphate Fluocortolone caproate with fluocortolone pivalate and cinchocaine

Presentation

Inj 50 mg Tab 10 mg Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1% Cap 20 mg Tab disp 20 mg, scored Tab 0.8 mg & 5 mg Crm 2% & Oint 2% Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg TDDS 10 mg Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml Inj 10 iu per ml, 5 ml Crm 1% Tab 5 mg & 20 mg Rectal foam 10%, CFC-Free Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Oral liq 100 mg per 5 ml, 200 ml Tab 10 mg & 25 mg Tab 2.5 mg Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Inj 50 mg per ml, 2 ml Tab long-acting 60 mg

Brand Name Expiry Date*

Fludara Fludara Ultraproct Ultraproct 2011 2010

Fluorometholone Fluoxetine hydrochloride Folic Acid Fusidic acid Gentamicin sulphate Gliclazide Glipizide Glyceryl trinitrate

Flucon Fluox Fluox Apo-Folic Acid Foban Pfizer Apo-Gliclazide Minidiab Lycinate Nitrolingual pumpspray Nitroderm TTS 5 Nitroderm TTS 10 Serenace Serenace Serenace AstraZeneca PSM Douglas Colifoam Locoid DP Lotn HC Methopt Buscopan Gastrosoothe Fenpaed Tofranil Napamide Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Ferrum H Duride

2009 2010 2009 2010 2009 2011 2011 2011

Haloperidol

2010 2009 2009 2011 2009 2009 2010 2011 2011 2011 2010 2009 2009 2010

Heparinised saline Hydrocortisone Hydrocortisone acetate Hydrcortisone butyrate Hydrocortisone with wool fat and mineral oil Hypromellose Hysocine N-butylbromide Ibuprofen Imipramine hydrochloride Indapamide Ipratropium bromide

Iron polymaltose Isosorbide mononitrate

2011 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 9

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Isotretinoin Itraconazole Ketoconazole Lactulose Levobunolol Levodopa with benserazide

Presentation

Cap 10 mg Cap 20 mg Cap 100 mg Shampoo 2%, 100 ml OP Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Isotane 10 Isotane 20 Sporanox Sebizole Duphalac Betagan Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250 Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Ativan Mayne Derbac M A-Lices Ludiomil Colofac Provera Pentasa Arrow-Metformin Methatabs AFT Methotrexate Ebewe Methotrexate Ebewe Methoblastin Prodopa Prodopa Prodopa 2009 2010 2010 2010 2009 2010 2011 2010 2010 2009

Lignocaine hydrochloride

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Lorazepam Magnesium sulphate Malathion Maldison Maprotiline hydrochloride Mebeverine hydrochloride Medroxyprogesterone acetate Mesalazine Metformin hydrochloride Methadone hydrochloride Methotrexate

Tab 1 mg & 2.5 mg Inj 49.3% Liq 0.5% Shampoo 1% Tab 25 mg & 75 mg Tab 135 mg; 90 tab Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Tab 500 mg & 850 mg Tab 5 mg Powder 1 g Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 2.5 mg & 10 mg Tab 125 mg; 100 tab Tab 250 mg; 100 tab Tab 500 mg; 100 tab

2009 2009 2010 2010 2009 2011 2010 2009 2009 2010 2009 2011 2009 2011

Methyldopa

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 10

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Methylphenidate hydrochloride

Presentation

Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg Tab 4 mg & 100 mg Crm 0.1% and oint 0.1% Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab long-acting 200 mg Cap 250 mg Crm 2% Tab 2.5 mg & 5 mg Tab 200 µg Tab 150 mg & 300 mg Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml Tab 40 mg & 80 mg Tab 50 mg Tab 250 mg Tab 500 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 50 mg & 500 mg Tab long-acting 20 mg

Brand Name Expiry Date*

Rubifen SR Rubifen Rubifen Medrol Advantan Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Slow-Lopresor Metopirone Multichem Gutron Cytotec Apo-Moclobemide RA-Morph RA-Morph RA-Morph RA-Morph Mayne Mayne Mayne Mayne m-Eslon Sevredol Mayne Apo-Nadolol ReVia Noflam 250 Noflam 500 Sonaflam AstraZeneca Viramune Suspension Apo-Nicotinic Acid Nyefax Retard 2009 2010 2010 2009 2010 2010 2009 2009 2009 2009

Methylprednisolone Methylprednisolone aceponate Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol tartrate Metyrapone Miconazole nitrate Midodrine Misoprostol Moclobemide Morphine hydrochloride

2009 2009 2011 2011 2009

2011 2009 2009 2011 2009 2009 2009 2009

Morphine sulphate

2011 2009

Morphine tartrate Nadolol Naltrexone hydrochloride Naproxen Naproxen sodium Neostigmine Nevirapine Nicotinic acid Nifedipine

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 11

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Norethisterone Nortriptyline hydrochloride Nystatin

Presentation

Tab 5 mg Tab 350 µg Tab 10 mg; 100 tab Tab 25 mg; 250 tab Oral liq 100,000 u per ml, 24 ml OP Cap 500,000 u Tab 500,000 u Vaginal crm 100,000 u per 5 g with applicators Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml and 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Tab 20 mg Tab 40 mg

Brand Name Expiry Date*

Primolut N Noriday 28 Norpress Norpress Nilstat Nilstat Nilstat Nilstat Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Dr Reddy’s Pantoprazole Dr Reddy’s Pantoprazole Paracare Junior Paracare Double Strength Lacri-Lube Loxamine Permax Permax Pexsig AFT AFT Cilicaine VK Cilicaine VK Prefrin Coloxyl Vistil Vistil Forte Span-K 2011 2009 2011 2011 2010 2009 2010 2010 2010 2009

Ondansetron Oxybutynin Oxycodone hydrochloride Oxytocin

Pamidronate disodium

2011

Pantoprazole

2010

Paracetamol

Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Eye oint with soft white paraffin Tab 20 mg Tab 0.25 mg Tab 1 mg Tab 100 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg Eye drops 0.12% Oral drops 10%, 30 ml OP Eye drops 1.4% Eye drops 3% Tab long-acting 600 mg

2011

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Pergolide Perhexiline maleate Phenoxymethylpenicillin (Penicillin V)

2010 2010 2011 2009 2010

Phenylephrine hydrochloride Poloxamer Polyvinyl alcohol Potassium chloride

2010 2011 2011 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 12

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Prazosin hydrochloride Prednisone

Presentation

Tab 1 mg, 2 mg & 5 mg Tab 1 mg; 500 tab Tab 2.5 mg; 500 tab Tab 5 mg; 500 tab Tab 20 mg; 500 tab Cassette Inj 1.5 mega u; 5 inj Tab 10 mg Tab 25 mg Tab 50 mg Tab 5 mg; 10 mg & 20 mg Tab 10 mg with hydroclorothiazide 12.5 mg Tab 20 mg with hydroclorothiazide 12.5 mg Tab 200 mg Tab 300 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 150 mg & 300 mg Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg Tab 5 mg Inj 0.9%, 5 ml & 10 ml Grans eff 4 g sachets Nasal spray 4% Tab 500 mg Tab EC 500 mg Liq Soln 2.3%; 500 ml and 1,000 ml

Brand Name Expiry Date*

Apo-Prazo Apo-Prednisone Apo-Prednisone Apo-Prednisone Apo-Prednisone MDS Quick Card Cilicaine Allersoothe Apo-Pyridoxine Accupril Accuretic 10 Accuretic 20 Q 200 Q 300 Peptisoothe Mycobutin Arrow-Roxithromycin Asthalin Asthalin Salapin Duolin Apo-Selegiline AstraZeneca Ural Rex Salazopyrin Salazopyrin EN Midwest Pinetarsol 2009 2010 2010 2009 2009 2010 2009 2009 2009 2010 2009 2009 2010 2011 2010 2011

Pregnancy tests - HCG urine Procaine penicillin Promethazine Pyridoxine hydrochloride Quinapril Quinapril with hydroclorothiazide

2009 2011 2011 2009 2011 2011

Quinine sulphate Ranitidine hydrochloride Rifabutin Roxithromycin Salbutamol

Salbutamol with ipratropium bromide Selegiline hydrochloride Sodium chloride Sodium citro-tartrate Sodium cromoglycate Sulphasalazine Syrup (pharmaceutical grade) Tar with triethanolamine lauryl sulphate and fluorescein sodium Temazepam Terbinafine Testosterone cypionate Tetracosactrin

Tab 10 mg; 25 tab Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 mcg Inj 1 mg per ml, 1 ml

Normison Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot

2011 2011 2011 2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 13

Sole Subsidised Supply Products – cumulative to April 2009

Generic Name

Timolol maleate

Presentation

Eye drops 0.25% Eye drops 0.5% Tab 10 mg Tab 50 mg Crm 0.02%; 100 g OP Oint 0.02%; 100 g OP Inj 40 mg per ml, 1 ml; 5 inj 0.1% in Dental Paste USP Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Tab 300 mg; 50 tab Cap 300 mg Inj 50 mg per ml, 10 ml; 1 inj Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab (BPC cap strength) Tab, strong, BPC Purified for injection 20 ml Ointment BP Cap 220 mg; 100 cap Tab 7.5 mg

Brand Name Expiry Date*

Apo-Timop Apo-Timop Apo-Timol Apo-Thiamine Aristocort Aristocort Kenacort-A40 Oracort Kenacomb 2011 2009 2009 2011 2011 2009

Thiamine hydrochloride Triamcinolone acetonide

Triamcinolone acetonide with gramicidin, neomycin and nystatin Trimethoprim Ursodeoxycholic acid Vancomycin hydrochloride Vincristine sulphate Vitamins Vitamin B complex Water Zinc and castor oil Zinc sulphate Zopiclone April changes in bold type.

TMP Actigall Pacific Mayne Mayne Healtheries Apo-B-Complex Multichem PSM Zincaps Apo-Zopiclone

2011 2011 2011 2009 2009 2009 2009 2011 2011 2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 14

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 April 2009

87 121 122 DANAZOL – Retail pharmacy-Specialist Cap 100 mg ............................................................................ 56.66 APOMORPHINE HYDROCHLORIDE ▲ Inj 10 mg per ml, 2 ml ............................................................. 50.43 ROPINIROLE HYDROCHLORIDE ▲ Tab 0.25 mg ............................................................................. 7.90 ▲ Tab 1 mg ................................................................................ 40.32 ▲ Tab 2 mg ................................................................................ 60.72 ▲ Tab 5 mg ................................................................................ 90.00 CLOZAPINE – Hospital pharmacy [HP4] Tab 25 mg .............................................................................. 26.74 Tab 100 mg ............................................................................ 69.30 ATOMOXETINE HYDROCHLORIDE – Special Authority see SA0951 below Cap 10 mg ............................................................................ 107.03 Cap 18 mg ............................................................................ 107.03 Cap 25 mg ............................................................................ 107.03 Cap 40 mg ............................................................................ 107.03 Cap 60 mg ............................................................................ 107.03 Cap 80 mg ............................................................................ 139.11 Cap 100 mg .......................................................................... 139.11 100 5 84 84 84 84 100 100 28 28 28 28 28 28 28 ✔ Azol

✔ Apomine

✔ Ropin ✔ Ropin ✔ Ropin ✔ Ropin

123

✔ Clozaril ✔ Clozaril

129

✔ Strattera ✔ Strattera ✔ Strattera ✔ Strattera ✔ Strattera ✔ Strattera ✔ Strattera

➽ SA0951 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and 2 Once-daily dosing; and 3 Any of the following: 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine. Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Note: A “subsidised formulation of a stimulant” refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets. 136 GEMCITABINE HYDROCHLORIDE – PCT only – Special Authority see SA0877 on the next page Inj 1 g ................................................................................... 245.00 1 ✔ Gemcitabine Ebewe Inj 200 mg .............................................................................. 49.00 1 ✔ Gemcitabine Ebewe ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings – effective 1 April 2009 (continued)

182 FOOD THICKENER – Special Authority see SA0595 above – Hospital pharmacy [HP3] Powder ................................................................................... 91.20 6 kg ✔ Resource Thicken Up

Effective 1 March 2009

29 OMEPRAZOLE ❋ Inj 40 mg ................................................................................ 38.20 PANTOPRAZOLE ❋ Inj 40 mg .................................................................................. 8.75 5 ✔ Dr Reddy’s Omeprazole ✔ Pantocid I.V

29 33

GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly Glucose/test strips................................................................... 22.00 50 test OP ✔ Optium 5 second test SIMVASTATIN – see prescribing guidelines on page 49 ❋ Tab 10 mg ................................................................................ 2.05 ❋ Tab 20 mg ................................................................................ 3.00 ❋ Tab 40 mg ................................................................................ 5.35 ❋ Tab 80 mg .............................................................................. 11.65 CILAZAPRIL ❋ Tab 2.5mg ................................................................................ 4.10 ❋ Tab 5 mg .................................................................................. 6.01 MEBENDAZOLE Tab 100 mg ............................................................................ 17.28 90 90 90 90 28 28 24

✔ Arrow-Simva ✔ Arrow-Simva ✔ Arrow-Simva ✔ Arrow-Simva

✔ Inhibace ✔ Inhibace

88 90

✔ De-Worm

AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg – Up to 30 tab available on a PSO ............................................................... 25.10 100 IBUPROFEN ❋ Tab 200 mg ............................................................................ 16.00 1000

✔ Synermox ✔ Ethics Ibuprofen

104

Effective 1 February 2009

73 CONDOMS ❋ 56 mm extra strength - Up to 144 dev available on a PSO ........ 13.36 ❋ 56 mm - Up to 144 dev available on a PSO .............................. 13.36 MEBENDAZOLE – Only on a prescription Tab 100 mg .............................................................................. 2.53 (7.43) 144 144 ✔ Durex Extra Safe ✔ Durex Select Flavours

4 Vermox

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings – effective 1 February 2009 (continued)

114 TRANYLCYPROMINE SULPHATE Tab 10 mg .............................................................................. 22.94 50 ✔ Parnate S29

Effective 1 January 2009

109 ALLOPURINOL ❋ Tab 100 mg .............................................................................. 5.44 ❋ Tab 300 mg .............................................................................. 4.03 (Note: Progout tabs 100 mg and 300 mg to be delisted 1 June 2009) CLOZAPINE – Hospital pharmacy [HP4] Oral liq 50 mg per ml ............................................................... 34.65 250 100 ✔ Apo-Allopurinol ✔ Apo-Allopurinol

123 184

100 ml

✔ Clopine

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Italian long style spaghetti .......................................................... 2.00 220 g (3.11)

Orgran

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 April 2009

63 ISOTRETINOIN see Special Authority SA0955 Cap 10 mg………………………………………………….36.00 Cap 20 mg…………………………………………….……47.50 100 100 ✔ Isotane 10 ✔ Isotane 20

➽ SA0955 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has had an adequate trial on other available treatments and has failed these treatments or these are contraindicated; and 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and 4 Either: 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or 4.2 Patient is male. Note Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it. Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has had an adequate trial on other available treatments and has failed these treatments or these are contraindicated; and 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and 4 Either: 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or 4.2 Patient is male. Note Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2009 (continued)

69 ACITRETIN see Special Authority SA0954 Cap 10 mg………………………………………………….75.80 Cap 25 mg…………………………………………….……162.96 100 100 ✔ Neotigason ✔ Neotigason

➽ SA0954 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and 3 Either: 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or 3.2 Patient is male. Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and 3 Either: 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or 3.2 Patient is male. Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it 100 PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA0952 0802 below – Hospital pharmacy [HP3] See prescribing guideline on page 98 Inj 135 µg prefilled syringe ................................................... 362.00 1 Inj 180 µg prefilled syringe ................................................... 450.00 1 Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ................................................................................ 1,799.68 1 OP Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ................................................................................ 1,975.00 Inj 180 µg prefilled syringe × 4 with ribavirin tab 200 mg × 112 ............................................................................... 2,059.84 1 OP 1 OP

✔ Pegasys ✔ Pegasys ✔ Pegasys RBV Combination Pack ✔ Pegasys RBV Combination Pack ✔ Pegasys RBV Combination Pack continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2009 (continued)

continued... Inj 180 µg prefilled syringe × 4 with ribavirin tab 200 mg × 168 ................................................................................ 2,190.00 1 OP ✔ Pegasys RBV Combination Pack

➽ SA0802 Special Authority for Subsidy Initial application — (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria: Either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 2 Patient has chronic hepatitis C and is co-infected with HIV. Note: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. Initial application —(genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2 Either: 2.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or 2.2 is unsuitable for liver biopsy due to coagulopathy. ➽ SA0952 Special Authority for Subsidy Initial application – (Hepatitis C -genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any relevant specialist. Approvals valid for 48 weeks for applications meeting the following criteria: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 2 Patient has chronic hepatitis C and is co-infected with HIV. Note: Consider stopping treatment if serum HCV RNA level at Week 12 remains detectable by PCR and has not reduced by at least 2 logs from the baseline level as this is predictive of treatment failure. Note: Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (<50IU/mL) AND Baseline serum HCV RNA is <400,000IU/mL. Initial application – (Hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any relevant specialist. Approvals valid for 6 months for applications where the patient has chronic hepatitis C, genotype 2 or 3 infection. Initial application – (Hepatitis B) only from a gastroenterologist, infectious disease specialist, or general physician. Approved dose is 180 mcg once weekly. Approvals valid for 48 weeks unless notified for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B treatment-naïve; and 3 ALT > 2 times Upper Limit of Normal; and 4 HBV DNA < 10 log10 IU/mL; and 5 Either: 5.1 HBeAg positive; or 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2); and 6 Compensated liver disease: and 7 No continuing alcohol abuse or intravenous drug use; and 8 Not co-infected with HCV, HIV or HDV; and 9 Neither ALT nor AST greater than 10 times upper limit of normal; and 10 No history of hypersensitivity or contraindications to pegylated interferon; Note: The recommended dose of Pegylated Interferon-alpha 2a is 180 mcg once weekly. In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alpha 2a dose should be reduced to 135 mcg once weekly. In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines. Pegylated Interferon-alpha 2a is not approved for use in children Patients pay a manufacturer’s surcharge when S29 Unapproved medicine supplied under Section 29 the Manufacturer’s Price is greater than the Subsidy ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2009 (continued)

101 PEGYLATED INTERFERON ALPHA-2B WITH RIBAVIRIN – Special Authority see SA0953 0846 below – Hospital pharmacy [HP3] See prescribing guideline on page 98 Inj 50 µg × 4 with ribavirin cap 200 mg × 112 .................. 1,080.40 1 OP ✔ Pegatron Combination Therapy Inj 50 µg × 4 with ribavirin cap 200 mg × 84 ....................... 976.80 1 OP ✔ Pegatron Combination Therapy Inj 80 µg × 4 with ribavirin cap 200 mg × 140 .................. 1,583.60 1 OP ✔ Pegatron Combination Therapy Inj 80 µg × 4 with ribavirin cap 200 mg × 168 .................. 1,687.20 1 OP ✔ Pegatron Combination Therapy Inj 80 µg × 4 with ribavirin cap 200 mg × 84 .................... 1,376.40 1 OP ✔ Pegatron Combination Therapy Inj 100 µg × 4 with ribavirin cap 200 mg × 112 ................ 1,746.40 1 OP ✔ Pegatron Combination Therapy Inj 100 µg × 4 with ribavirin cap 200 mg × 84 .................. 1,642.80 1 OP ✔ Pegatron Combination Therapy Inj 120 µg × 4 with ribavirin cap 200 mg × 140 ................ 2,116.40 1 OP ✔ Pegatron Combination Therapy Inj 120 µg × 4 with ribavirin cap 200 mg × 84 ................. 1,909.20 1 OP ✔ Pegatron Combination Therapy Inj 150 µg × 4 with ribavirin cap 200 mg × 140 ............... 2,516.00 1 OP ✔ Pegatron Combination Therapy Inj 150 µg × 4 with ribavirin cap 200 mg × 168 ............... 2,619.60 1 OP ✔ Pegatron Combination Therapy Inj 150 µg × 4 with ribavirin cap 200 mg × 84 ................. 2,308.80 1 OP ✔ Pegatron Combination Therapy ➽ SA0846 Special Authority for Subsidy Initial application from any specialist. Approvals valid for 11 months for applications meeting the following criteria: Either: 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or 2 Both: 2.1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and 2.2 Either: 2.2.1 has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent); or 2.2.2 is unsuitable for liver biopsy due to coagulopathy. Note: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure. continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 April 2009 (continued)

continued... ➽ SA0953 Special Authority for Subsidy Initial application- from any relevant specialist. Approvals valid for 11 months where the patient has an existing current Special Authority. Note: Existing current approvals are still valid but no new applications will be accepted. ONDANSETRON – Retail pharmacy-Specialist Tab 4 mg ................................................................................ 17.18 10 ✔ Zofran Tab disp 4 mg ......................................................................... 17.18 10 ✔ Zofran Zydis Tab 8 mg ................................................................................ 33.89 20 ✔ Zofran Tab disp 8 mg ......................................................................... 20.43 10 ✔ Zofran Zydis a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. ROPINIROLE HYDROCHLORIDE - Retail pharmacy-Specialist ▲ Tab 0.25 mg ............................................................................. 7.90 ▲ Tab 0.25 mg ........................................................................... 31.50 ▲ Tab 0.25 mg x 42, 0.5 mg x 42 and 1 mg x 21 ........................ 35.70 ▲ Tab 0.5 mg x 42, 1 mg x 42 and 2 mg x 63 ........................... 122.11 ▲ Tab 1 mg ................................................................................ 40.32 ▲ Tab 1 mg ................................................................................ 67.20 ▲ Tab 2 mg ................................................................................ 60.72 ▲ Tab 2 mg .............................................................................. 101.21 ▲ Tab 5 mg ................................................................................ 90.00 ▲ Tab 5 mg .............................................................................. 150.00 84 210 105 OP 147 OP 84 84 84 84 84 84 ✔ Ropin ✔ Requip ✔ Requip Starter Pack ✔ Requip Follow-On Pack ✔ Ropin ✔ Requip ✔ Ropin ✔ Requip ✔ Ropin ✔ Requip

120

122

Effective 1 March 2009

61 63 GLYCERYL TRINITRATE ❋ Tab 600 µg - Up to 100 tab available on a PSO ........................ 8.00 100 OP Lycinate S29

ISOTRETINOIN see Special Authority SA0947 – Hosp pharmacy [HP3]-Specialist prescription Specialist must be a dermatologist Cap 10 mg .............................................................................. 36.00 100 ✔ Isotane 10 Cap 20 mg .............................................................................. 47.50 100 ✔ Isotane 20 ➽ SA0947 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has had an adequate trial on other available treatments and has failed these treatments or these are contraindicated. 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice. 3 Patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment. continued...

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2009 (continued)

continued... Note: Applicants need to have an up to date knowledge of the treatment options for acne and the safety issues around isotretinoin and be competent to prescribe it. Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. Renewal application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has had an adequate trial on other available treatments and has failed these treatments or is contraindicated. 2. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant vocational scope of practice. 3. Patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment. Note: Applicants need to have an up to date knowledge of the treatment options for acne and the safety issues around isotretinoin and be competent to prescribe it. Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. 69 ACITRETIN see Special Authority SA0946 – Hosp pharmacy [HP3]-Specialist prescription Specialist must be a dermatologist Cap 10 mg .............................................................................. 94.75 100 ✔ Neotigason Cap 25 mg ............................................................................ 203.70 100 ✔ Neotigason ➽ SA0946 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice. 2. Patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment. Note: Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it. Renewal application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice. 2. Patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment. Note: Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2009 (continued)

105 AURANOFIN - Retail pharmacy-Specialist Tab 3 mg ................................................................................ 68.99 (70.97) PENICILLAMINE - Retail pharmacy-Specialist Tab 125 mg ............................................................................ 61.93 Tab 250 mg ............................................................................ 98.98 SODIUM AUROTHIOMALATE - Retail pharmacy-Specialist Inj 10 mg per 0.5 ml ................................................................ 76.87 Inj 20 mg per 0.5 ml .............................................................. 113.17 Inj 50 mg per 0.5 ml .............................................................. 217.23 60 Ridaura 100 100 10 10 10 ✔ D-Penamine ✔ D-Penamine ✔ Myocrisin ✔ Myocrisin ✔ Myocrisin

105

108

ALENDRONATE SODIUM – Special Authority see SA0797948 on the preceding page – Retail pharmacy Tab 70 mg .............................................................................. 35.91 4 ✔ Fosamax Tab 70 mg with cholecalciferol 2800 iu.................................... 35.91 4 ✔ Fosamax Plus ➽ SA07970948 Special Authority for Subsidy Initial application – (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0. Initial application – (Underlying cause - glucocorticosteroid therapy) only from a relevant specialist or vocationally registered general practitioner from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months and has either; and 2 Either: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5); or 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically. Renewal – (Underlying cause was, and remains, glucocorticosteroid therapy) only from a relevant specialist or vocationally registered general practitioner from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents). Renewal – (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause – osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5); or

continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2009 (continued)

continued... 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0. Notes: a) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates. b) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. c) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. 108 ALENDRONATE SODIUM – Special Authority see SA0467949 above – Retail pharmacy Tab 40 mg ............................................................................ 133.00 30 ✔ Fosamax ➽ SA0467949 Special Authority for Subsidy Initial Initial application only from any relevant specialist practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from any relevant specialist practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. CALCITONIN – Hospital pharmacy [HP3]-Specialist ❋ Inj 100 iu per ml, 1 ml ........................................................... 110.00 BACLOFEN - Retail pharmacy-Specialist ❋ Tab 10 mg ................................................................................ 3.75 DANTROLENE SODIUM - Retail pharmacy-Specialist ❋ Cap 25 mg .............................................................................. 32.96 ❋ Cap 50 mg ............................................................................. 51.70 5 100 100 100

108 109 109

✔ Miacalcic

✔ Pacifen ✔ Dantrium ✔ Dantrium

109

PAMIDRONATE DISODIUM – Special Authority see SA0091 below – Hospital pharmacy [HP3] Inj 3 mg per ml, 5 ml ............................................................... 18.75 1 ✔ Pamisol Inj 3 mg per ml, 10 ml ............................................................. 37.50 1 ✔ Pamisol Inj 6 mg per ml, 10 ml ............................................................. 75.00 1 ✔ Pamisol continued... ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

continued... ➽ SA0091 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Changes to Restrictions - effective 1 March 2009 (continued)

Effective 1 February 2009

143 ANASTROZOLE Tab 1 mg – Higher subsidy of $240.00 per 30 with Special Authority see SA0942 ........................................................ 146.46 30 (240.00) Arimidex ➽ SA0942 Special Authority for Alternate Subsidy Initial application - New Patients - only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal woman; and 2 Patient has hormone receptor positive early breast cancer; and 3 Either: 3.1 The patient has a very clear history of intolerance to tamoxifen; or 3.2 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. Initial application – Patient has had a Special Authority approval for anastrozole prior to 1 December 2008 – only from a relevant specialist. Approval valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for anastrozole prior to 1 December 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone Ministry of Health Sector Services on 0800 243 666 for clarification if needed.

Changes to Restrictions - effective 1 January 2009

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS AND GALENICALS Standard Formulae 167 MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste .................................................. 275 g Methylhydroxybenzoate ............................................................. 1.5 g Water .................................................................................... 770 ml (Not subsidised as a laxative)

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 April 2009

26 SIMETHICONE ( price) ❋ Oral liq aluminium hydroxide 200 mg with magnesium hydroxide 200 mg and activated simethicone 20 mg per 5 ml ................ 1.50 (4.26) INSULIN ASPART ( price and subsidy) ▲ Inj 100 iu per ml, 3 ml ............................................................. 51.19 ▲ Inj 100 iu per ml, 10 ml ........................................................... 30.03 PROTAMINE SULPHATE ( price) ❋ Inj 10 mg per ml, 5 ml ............................................................. 22.40 (86.54) BEZAFIBRATE ( subsidy and price) ❋ Tab long-acting 400 mg ........................................................... 5.70 KETOCONAZOLE ( price) Crm 2% ..................................................................................... 1.00 (9.50) MICONAZOLE NITRATE ( price) ❋ Lotn 2% .................................................................................... 4.36 (10.03) 1) only on a prescription 2) not in combination ❋ Tincture 2% ............................................................................... 4.36 (12.10) 1) only on a prescription 2) not in combination 69 ACITRETIN – Special Authority see SA0946 below ( subsidy) Cap 10 mg ............................................................................. 75.80 Cap 25 mg ............................................................................ 162.96 30 15 g OP Nizoral 30 ml OP Daktarin 500 ml Mylanta P 5 1 ✔ NovoRapidPenfill ✔ NovoRapid

Artex ✔ Bezalip Retard

49 64

30 ml OP Daktarin

100 100

✔ Neotigason ✔ Neotigason

ETHAMBUTOL HYDROCHLORIDE – No patient co-payment payable ( price and subsidy) Tab 400 mg ............................................................................ 56.84 56 ✔ Myambutol S29 AURANOFIN ( price) Tab 3 mg ................................................................................ 68.99 HYALURODINASE ( price) Inj 1,500 iu per ml ................................................................... 18.32 (243.24) DIAZEPAM ( price and subsidy) Rectal tubes 5 mg – Up to 5 tube available on a PSO ............... 25.05 Rectal tubes 10 mg – Up to 5 tube available on a PSO ............. 30.50

105 109

60 10

✔ Ridaura

Hyalase 5 5

115

✔ Stesolid ✔ Stesolid

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 April 2009 (continued)

110 PARACETAMOL ( price and subsidy) ❋ Suppos 125 mg......................................................................... 7.49 ❋ Suppos 250 mg....................................................................... 14.40 TRIFLUOPERAZINE HYDROCHLORIDE ( price and  subsidy) Tab 1 mg .................................................................................. 9.83 Tab 2 mg ................................................................................ 14.64 Tab 5 mg ................................................................................ 16.66 182 20 20 100 100 100 ✔ Panadol ✔ Panadol ✔ Stelazine S29 ✔ Stelazine S29 ✔ Stelazine S29

124

GLUTEN FREE BREAD MIX – Special Authority see SA0722 above - Hospital pharmacy [HP3] ( price) Powder ..................................................................................... 3.93 1,000g OP (6.88) NZB Low Gluten Bread Mix 3.51 (10.51) Horleys Bread Mix GLUTEN FREE BREAD MIX – Special Authority see SA0722 above - Hospital pharmacy [HP3] ( price) Powder ..................................................................................... 4.77 1,000 g OP (8.57) Bakels Gluten Free Health Bread Mix GLUTEN FREE FLOUR– Special Authority see SA0722 above - Hospital pharmacy [HP3] ( price) Powder ..................................................................................... 5.62 2,000 g OP (17.42) Horleys Flour

182

Effective 1 March 2009

26 SODIUM ALGINATE ( price) ❋ Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg – peppermint flavour ................. 1.80 (8.60) ❋ Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) ...................................................... 1.50 (8.64) 29 OMEPRAZOLE ( price) ❋ Cap 10 mg ................................................................................ 2.14 (4.40) ❋ Cap 20 mg ................................................................................ 3.05 (4.70) ❋ Cap 40 mg ................................................................................ 3.59 (5.90) ❋ Inj 40 mg .................................................................................. 7.54 (7.73) CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE ( price) ❋ Adhesive gel 8.7% with cetalkonium chloride 0.01 % ................. 2.06 (5.25) MICONAZOLE ( price and subsidy) Oral gel 20 mg per g .................................................................. 8.70

S29

60 Gaviscon Double Strength 500 ml Gaviscon 30 Losec 30 Losec 30 Losec 1 Losec 15 g OP Bonjela 40 OP ✔ Daktarin

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 March 2009 (continued)

77 CLOTRIMAZOLE ( price) ❋ Vaginal cream 2% with applicators............................................. 3.44 (5.71) ALLOPURINOL ( subsidy) ❋ Tab 100 mg ............................................................................ 10.88 (11.45) ❋ Tab 300 mg ........................................................................... 20.15 (21.20) ASPIRIN ( subsidy) ❋ Tab EC 300 mg ......................................................................... 2.15 (8.10) DEXTROPROPOXYPHENE WITH PARACETAMOL ( price) Cap hydrochloride 32.5 mg with paracetamol 325 mg.............. 19.91 (33.14) MIDAZOLAM ( price and subsidy) Inj 1 mg per ml, 5 ml ............................................................... 10.75 (14.73) Inj 5 mg per ml, 3 ml ............................................................... 11.90 (19.64) TRIAZOLAM - Month restriction ( price) Tab 125 µg ............................................................................... 5.10 (6.50) Tab 250 µg ............................................................................... 4.10 (7.20) 25 g OP Clotrimaderm 2% 500 Progout 500 Progout 100 Aspec 300 500 Capadex 10 10 ✔ Hypnovel Pfizer ✔ Hypnovel Pfizer

109

110

111

129

100 Hypam 100 Hypam

145

OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA0563 below – Hospital pharmacy [HP3] ( subsidy) Inj 50 µg per ml, 1 ml .............................................................. 43.50 5 ✔ Sandostatin Inj 100 µg per ml, 1 ml ............................................................ 81.00 5 ✔ Sandostatin Inj 500 µg per ml, 1 ml .......................................................... 399.00 5 ✔ Sandostatin BEE VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Hospital pharmacy [HP3] ( subsidy) Maintenance kit – 6 vials 120 µg freeze dried venom, 6 diluent 1.8 ml............................................. 285.00 1 OP ✔ Albay Treatment kit – 1 vial 550 µg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml ........................................... 285.00 1 OP ✔ Albay WASP VENOM ALLERGY TREATMENT - Special Authority see SA0053 below – Hospital pharmacy [HP3] ( price and subsidy) Treatment kit (Paper wasp venom) - 1 vial 550 µg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml .............................. 285.00 1 OP ✔ Albay Treatment kit (Yellow jacket venom) – 1 vial 550 µg freeze dried vespula venom, 1 diluent 9 ml , 1 diluent 1.8 ml ............................. 285.00 1 OP ✔ Albay

150

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 February 2009

27 ZINC OXIDE ( price) Oint zinc oxide with balsam peru ................................................ 4.50 (6.67) Suppos zinc oxide with balsam peru .......................................... 4.47 (6.49) AMLODIPINE ( subsidy) ❋ Tab 5 mg .................................................................................. 2.20 ❋ Tab 10 mg ................................................................................ 3.54 50 g OP Anusol 12 Anusol 30 30 ✔ Calvasc ✔ Calvasc

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN ( price) Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Only on a prescription............ 3.49 15 g OP (6.60) AQUEOUS ( price) ❋ Crm........................................................................................... 2.28 UREA ( price) ❋ Crm 10% ................................................................................... 2.52 (3.07) TRIMIPRAMINE MALEATE ( subsidy and price) Cap 25 mg ................................................................................ 6.20 Cap 50 mg .............................................................................. 11.20 ANASTROZOLE ( price) Tab 1 mg .............................................................................. 146.46 CETIRIZINE HYDROCHLORIDE ( subsidy) ❋ Tab 10 mg ................................................................................ 1.99 (3.32) ❋ Oral liq 1 mg per ml ................................................................... 1.75 (2.75) 500 g 100 g OP

Viaderm KC ✔ Multichem

68 68

Nutraplus 100 100 30 90 Razene 100 ml OP Allerid C ✔ Tripress ✔ Tripress ✔ Arimidex

114

143 150

Effective 1 January 2009

29 OMEPRAZOLE ( subsidy and  price) ❋ Cap 10 mg ................................................................................ 2.14 (8.43) ❋ Cap 20 mg ................................................................................ 3.05 (9.00) ❋ Cap 40 mg ................................................................................ 3.59 (11.25) NIFEDIPINE ( subsidy and price) ❋ Tab long-acting 30 mg ............................................................ 10.70 ❋ Tab long-acting 60 mg ........................................................... 15.35 30 Losec 30 Losec 30 Losec 30 30 ✔ Arrow-Nifedipine XR ✔ Adefin XL ✔ Arrow-Nifedipine XR ✔ Adefin XL

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 January 2009 (continued)

68 AQUEOUS CREAM ( subsidy) ❋ Crm........................................................................................... 2.28 (2.37) CLOTRIMAZOLE ( subsidy) ❋ Vaginal crm 2% with applicators ................................................ 3.44 (3.99) AMOXYCILLIN ( subsidy) Drops 125 mg per 1.25 ml ........................................................ 2.67 (7.25) Inj 250 mg ................................................................................ 6.21 (6.32) Inj 500 mg ................................................................................ 7.12 (7.32) Inj 1 g ..................................................................................... 10.8 (11.00) 91 CIPROFLOXACIN ( subsidy) Tab 250 mg – Up to 5 tab available on a PSO ............................ 3.13 Tab 500 mg – Up to 5 tab available on a PSO ............................ 4.57 (8.31) Tab 750 mg – Up to 5 tab available on a PSO ............................ 7.04 PYRIDOSTIGMINE BROMIDE ( subsidy) ▲ Tab 60 mg .............................................................................. 40.08 PARACETAMOL ( price) Tab 500 mg - Up to 30 available on a PSO ................................. 1.38 (14.67) 137.81 (1,467.00) CITALOPRAM HYDROBROMIDE ( subsidy) ❋ Tab 20 mg ................................................................................ 1.26 (3.50) 119 120 METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL ( subsidy) Tab 5 mg with paracetamol 500 mg........................................... 6.77 60 500 g Multichem 25 g OP Clotrimaderm 2% 20 ml OP Amoxil Paediatric Drops 5 Ibiamox 5 Ibiamox 5 Ibiamox 28 28 28 100 150 Panadol 15,000 Panadol 28 ✔ Cipflox Cipflox ✔ Cipflox

104 110

✔ Mestinon

114

✔ Arrow-Citalopram ✔ Citalopram-Rex Celapram

✔ Paramax

HYOSCINE (SCOPOLAMINE) – Special Authority see SA0727 – Hospital Pharmacy [HP3] ( subsidy) Patches 1.5 mg ....................................................................... 11.95 2 ✔ Scopoderm TTS

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 January 2009 (continued)

123 CLOZAPINE – Hospital pharmacy [HP4] ( subsidy) Tab 25 mg .............................................................................. 13.37 13.37 26.74 Tab 50 mg .............................................................................. 17.33 34.65 Tab 100 mg ............................................................................ 34.65 34.65 69.30 Tab 200 mg ............................................................................ 55.45 110.90 50 50 100 50 100 50 50 100 50 100 ✔ Clopine ✔ Clozaril ✔ Clopine ✔ Clopine ✔ Clopine ✔ Clozaril ✔ Clopine ✔ Clopine ✔ Clopine ✔ Clopine

136

OXALIPLATIN – PCT only – Specialist – Special Authority see SA0900 ( subsidy and price) Inj 50 mg .............................................................................. 200.00 1 ✔ Eloxatin Inj 100 mg ............................................................................ 400.00 1 ✔ Eloxatin Inj 1 mg for ECP ........................................................................ 4.36 1 mg ✔ Baxter OCTREOTIDE (SOMATOSTATIN ANALOGUE) - Special Authority see SA0563 – Hospital pharmacy [HP3] ( subsidy) Inj 50 µg per ml,1 ml .............................................................. 25.65 (43.50) Inj 100 µg per ml, 1 ml ........................................................... 48.50 (81.00) Inj 500 µg per ml, 1 ml .......................................................... 175.00 (399.00) HYPROMELLOSE ( subsidy) ❋ Eye drops 0.5% ........................................................................ 2.00

146

5 Sandostatin 5 Sandostatin 5 Sandostatin

161

15 ml OP

✔ Methopt

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 January 2009 (continued)

184 GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital Pharmacy [HP3] ( price) Buckwheat Spirals ..................................................................... 2.00 250 g OP (3.11) Orgran Corn and Spinach Rigattini......................................................... 2.00 250 g OP (2.92) Orgran Corn and Vegetable Shells ......................................................... 2.00 250 g OP (2.92) Orgran Corn and Vegetable Spirals ........................................................ 2.00 250 g OP (2.92) Orgran Garlic and Parsley Shells ........................................................... 2.00 250 g OP (2.92) Orgran Rice and Corn Garden Herb Pasta .............................................. 2.00 250 g OP (2.92) Orgran Rice and Corn Lasagne Sheets .................................................. 2.00 200 g OP (3.82) Orgran Rice and Corn Macaroni ............................................................ 2.00 250 g OP (2.92) Orgran Rice and Corn Penne ................................................................. 2.00 250 g OP (2.92) Orgran Rice and Maize Pasta Spirals ..................................................... 2.00 250 g OP (2.92) Orgran Rice and Millet Spirals ............................................................... 2.00 250 g OP (3.11) Orgran Rice and corn spaghetti noodles ................................................ 2.00 375 g OP (2.92) Orgran Vegetable and Rice Spirals......................................................... 2.00 250 g OP (2.92) Orgran

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 April 2009

186 MULTIVITAMINS –Special Authority see SA0600 above – Hospital pharmacy [HP3] Oral liq ...................................................................................... 8.98 150 ml OP (13.50) Ketovite Syrup Liquid

Effective 1 March 2009

33 GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly Glucose/test strips................................................................... 22.00 50 test OP ✔ Optium ✔ Optium 10 second test

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Description

Effective 1 April 2009

69 COAL TAR SolnSolution BP – Only in combination .................................... 36.48 500 ml ✔ PSM 12.98 200 ml (16.20) David Craig Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod – Plain, refer, page 163 With or without other dermatological galenicals. COAL TAR WITH SALICYLIC ACID AND SULPHUR Soln 12% with salicylic acid 2% and sulphur 4 % oint ointment 0.1% ................................................................ 7.95 HYDROCORTISONE BUTYRATE Milky Emul Emulsion 0.1% ....................................................... 5.00 15.00 HYDROGEN PEROXIDE ❋ Soln Solution 20 vol – Maximum of 500 ml per prescription ....... 3.13 (7.00) MICONAZOLE NITRATE ❋ Tinc Tincture 2% ...................................................................... 4.36 (12.46) a) Only on a prescription b) Not in combination TAR WITH CADE OIL Bath emul emulsion 7.5% coal tar, 2.5% cade oil, 7.5% compound ..................................................... 9.70 (29.60)

40 g OP

✔ Coco-Scalp

30 ml OP ✔ Locoid Crelo 100 ml OP ✔ Locoid Crelo 500 ml PSM 30 ml OP Daktarin

350 ml Polytar Emollient

Effective 1 January 2009

38 CALCIUM Tab eff 1 g (elemental) ............................................................. 6.54 30 ✔ Calsource

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 February 2009

21 3.4 Original packs, and certain Antibiotics 3.4.2 If a Community Pharmaceutical is the liquid form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more of standard packs of the Community Pharmaceutical, Subsidy will only be made paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of any the pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. In such cases all of that pack or those packs is eligible for subsidy. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: (i) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and (ii) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim for a whole pack (which includes a wastage amount) and then dispense the wastage amount for a subsequent prescription.

Changes to PSO

Effective 1 March 2009

GLYCERYL TRINITRATE Tab 600 µg ...................................100

Changes to Sole Subsidised Supply

Effective 1 April 2009

For the list of new Sole Subsidised Supply products effective 1 April 2009 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 6-14.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 April 2009

68 AQUEOUS CREAM ❋ Crm........................................................................................... 2.28 (2.37) AMOXYCILLIN Drops 125 mg per 1.25 ml ........................................................ 2.67 (7.25) Inj 250 mg ................................................................................ 6.21 (6.32) Inj 500 mg ................................................................................ 7.12 (7.23) Inj 1 g – Up to 5 inj available on a PSO..................................... 10.81 (11.00) 91 CIPROFLOXACIN Tab 250 mg – Up to 5 tab available on a PSO ............................ 3.13 Tab 500 mg – Up to 5 tab available on a PSO ............................ 4.57 (8.31) CITALOPRAM HYDROBROMIDE ❋ Tab 20 mg ................................................................................ 1.26 (3.50) 186 PHENYL FREE PASTA – Special Authority see SA0733 – Hospital pharmacy [HP3] Macaroni ................................................................................. 10.65 500 g OP (11.91) 500 g Multichem 20 ml OP Amoxil Paediatric Drops 5 Ibiamox 5 Ibiamox 5 Ibiamox 28 28 ✔ Cipflox Cipflox 28 ✔ Arrow-Citalopram ✔ Citalopram-Rex Celapram

114

Loprofin

Effective 1 March 2009

59 91 VERAPAMIL HYDROCHLORIDE ❋ Tab 40 mg ................................................................................ 4.75 FLUCLOXACILLIN SODIUM Inj 250 mg ............................................................................... 4.50 (4.66) Inj 500 mg ................................................................................ 5.20 (5.45) Inj 1 g ....................................................................................... 7.00 (7.54) 100 5 Flucloxin 5 Flucloxin 5 Flucloxin ✔ Verpamil

174

ORAL FEED 1KCAL/ML – Special Authority see SA0594 on the preceding page – Hospital pharmacy [HP3] Liquid (chocolate) ..................................................................... 1.78 237ml OP ✔ Resource Diabetic

Effective 1 February 2009

160 POLYVINYL ALCOHOL ❋ Eye drops 1.4 % ........................................................................ 2.68 ❋ Eye drops 3 % ........................................................................... 3.75 15 ml OP 15 ml OP ✔ Liquifilm Tears ✔ Liquifilm Forte

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 January 2009

29 OMEPRAZOLE ❋ Cap 10 mg ................................................................................ 2.14 (5.95) ❋ Cap 20 mg ................................................................................ 3.05 (5.95) ❋ Cap 40 mg ................................................................................ 3.59 (8.84) NORTRIPTYLINE HYDROCHLORIDE Tab 25 mg .............................................................................. 34.90 30 Omezol 30 Omezol 30 Omezol 500 ✔ Norpress

114 184

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital Pharmacy [HP3] Garlic and Parsley spirals .......................................................... 2.00 250 g (2.63)

Orgran

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 May 2009

53 DOXAZOSIN MESYLATE ❋ Tab 2 mg ................................................................................. 4.81 Note – the 500 tablet pack listed 1 November 2008 OESTRADIOL VALERATE – See prescribing guideline ❋ Tab 2 mg ................................................................................. 4.12 PARACETAMOL ❋ Tab 500 mg – Up to 30 tab available on a PSO ........................ 13.23 100 ✔ Apo-Doxazosin

81 110

28 1,440

✔ Progynova ✔ Panadol

Effective 1 June 2009

53 DOXAZOSIN MESYLATE ❋ Tab 4 mg .................................................................................. 6.37 Note – the 500 tablet pack listed 1 December 2008 ALLOPURINOL Tab 100 mg ............................................................................ 10.88 (11.45) Tab 300 mg ............................................................................ 20.15 (21.20) CARBAMAZEPINE ❋ Tab 200 mg ........................................................................ 29.06 Note – the 100 tablet pack size listed 1 December 2008 100 ✔ Apo-Doxazosin

109

500 Progout 500 Progout 200 ✔ Tegretol

115

Effective 1 July 2009

48 WATER 1) on a prescription or Practitioner’s Supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) on a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops Purified for inj 2 ml – Up to 5 ink available on a PSO ................ 21.90 50 ✔ Baxter CROTAMITON a) Only on a prescription b) Not in combination Lotn 10% .................................................................................. 7.56 (7.70) FLUOROURACIL SODIUM Inj 25 mg per ml, 20 ml – PCT only – Specialist ....................... 55.60

50 ml Eurax 10 ✔ Mayne

136 177

PAEDIATRIC ORAL FEED 1.5KCAL/ML –Special Authority see SA0986 – Hospital pharmacy [HP3] Liquid (chocolate) ..................................................................... 1.27 200 ml OP ✔ Resource Just for Kids Liquid (vanilla)........................................................................... 1.27 200 ml OP ✔ Resource Just for Kids ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 July 2009 (continued)

184 GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Corn and Parsley fettucine ......................................................... 2.00 250 g OP (2.63)

Orgran

Effective 1 August 2009

45 48 51 MENADIONE SODIUM BISULPHITE ❋ Tab 10 mg ................................................................................ 4.75 HEPARINISED SALINE ❋ Inj 100 iu per ml, 2 ml ............................................................... 8.30 SIMVASTATIN ❋ Tab 10 mg ................................................................................ 1.27 8.33 ❋ Tab 20 mg ................................................................................ 1.54 10.13 ❋ Tab 40 mg ................................................................................ 2.74 18.00 ❋ Tab 80 mg ................................................................................ 3.18 21.00 MEBENDAZOLE Tab 100 mg .............................................................................. 3.79 (7.59) AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg Up to 30 tab available on a PSO ............................................. 6.40 IBUPROFEN ❋ Tab 200 mg .............................................................................. 1.78 100 10 30 30 30 30 ✔ K-Thrombin ✔ Hospira S29 ✔ SimvaRex ✔ Lipex ✔ SimvaRex ✔ Lipex ✔ SimvaRex ✔ Lipex ✔ SimvaRex ✔ Lipex

6 Vermox

20 100

✔ Augmentin ✔ I-Profen

104 174

ORAL FEED 1KCAL/ML –Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid (chocolate) ..................................................................... 1.78 237 ml OP ✔ Resource Diabetic

Effective 1 September 2009

33 GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the Prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; Blood/glucose test strips ......................................................... 22.00 50 test OP ✔ Optium 10 second test GLYCEROL ❋ Suppos 2.55 g – Only on a prescription ..................................... 3.12 12 ✔ Fleet Glycerin Suppositories

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 September 2009 (continued)

57 LABETALOL ❋ Inj 5 mg per ml, 5 ml ............................................................... 14.77 (22.15) 5

Trandate S29

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Omly on a prescription........... 3.00 15 g OP ETHINYLOESTRADIOL WITH GESTODENE ❋ Tab 30 µg with gestodene 75 µg and 7 inert tab ........................ 6.62 (16.50) ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab ethinyloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinyloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab ......................................................................... 6.62 (14.49) TRIAMCINOLONE ACETONIDE Inj 10 mg per ml, 1 ml ............................................................. 11.11 DICLOXACILLIN Cap 250 mg .............................................................................. 2.47 (4.35) Cap 500 mg .............................................................................. 3.83 (8.65) ROPINIROLE HYDROCHLORIDE ▲ Tab 0.25 mg ........................................................................... 31.50 ▲ Tab 0.25 mg x 42, 0.5 mg x 42 and 1 mg x 21 ........................ 35.70 ▲ Tab 0.5 mg x 42, 1 mg x 42, and 2 mg x 6 .............................. 22.11 ▲ Tab 1 mg ................................................................................ 67.20 ▲ Tab 2 mg .............................................................................. 101.21 ▲ Tab 5 mg .............................................................................. 150.00 84

✔ Kenacomb

Minulet 28

84 Triphasil 28 5 24 Diclocil 24 Diclocil 210 105 OP 147 OP 84 84 84 ✔ Requip ✔ Requip Starter Pack ✔ Requip Follow-on Pack ✔ Requip ✔ Requip ✔ Requip ✔ Kenacort-A

80 90

122

174

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 on the preceding page – Hospital pharmacy [HP3] Liquid ........................................................................................ 7.50 1,000 ml OP ✔ Resource Diabetic TF RTH

Effective 1 October 2009

53 CILAZAPRIL Tab 2.5 mg ............................................................................... 4.39 Tab 5 mg .................................................................................. 6.44 INDOMETHACIN ❋ Cap 50 mg ................................................................................ 6.95 30 30 100 ✔ Inhibace ✔ Inhibace ✔ Rheumacin

105

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 October 2009 (continued)

121 APOMORPHINE HYDROCHLORIDE ▲ Inj 10 mg per ml, 2 ml ............................................................. 50.43 ▲ Inj 10 mg per ml, 1 ml ............................................................. 50.53 5 5 ✔ APO-go S29 ✔ Mayne

170

CARBOHYDRATE SUPPLEMENT – Special Authority – Hospital Pharmacy [HP3] Powder ..................................................................................... 1.14 350 g OP (7.85)

Polycose

176

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority – Hospital Pharmacy [HP3] Liquid (strawberry) .................................................................... 1.27 237 ml OP ✔ Pediasure Liquid (chocolate) ..................................................................... 1.27 237 ml OP ✔ Pediasure

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 April 2009

AMIKACIN SULPHATE (delisting date) Inj 250 mg per ml, 2 ml ..................Amikin Note- This product will be delisted 1 July 2009 15.00 1 1% Sept-06 (B)

APOMORPHINE HYDROCHLORIDE (new listing) Inj 10 mg per ml, 2 ml ....................Apomine 50.43 5 Note – The Mayne brand of Apomorphine hydrochloride inj 10 mg per ml, 1 ml will be delisted from 1 October 2009. ATOMOXETINE HYDROCHLORIDE (new listing) Cap 10 mg .....................................Strattera Cap 18 mg .....................................Strattera Cap 25 mg .....................................Strattera Cap 40 mg .....................................Strattera Cap 60 mg .....................................Strattera Cap 80 mg .....................................Strattera Cap 100 mg ...................................Strattera CLOZAPINE (new listing) Tab 25 mg......................................Clozaril Tab 100 mg ...................................Clozaril 107.03 107.03 107.03 107.03 107.03 139.11 139.11 26.74 69.30 28 28 28 28 28 28 28 100 100

DANAZOL (new listing) Cap 100 mg ...................................Azol 56.66 100 Note - D Zol brand of Danazol cap 100 mg 30 pack size to be delisted 1 October 2009 DIAZEPAM ( price) Rectal tubes 5 mg ..........................Stesolid Rectal tubes 10 mg ........................Stesolid 25.05 30.50 5 5 1 1 1% 1% Jun-09 Jun-09 Gemzar Hospira Gemzar Hospira Losec Losec IV

GEMCITABINE HYDROCHLORIDE (new listing and HSS) Inj 200 mg......................................Gemcitabine Ebewe49.00 Inj 1 g.............................................Gemcitabine Ebewe245.00 OMEPRAZOLE (addition of HSS) Inj 40 mg........................................Dr Reddy’s Omeprazole Inf 40 mg .......................................Dr Reddy’s Omeprazole PARACETAMOL ( price) Suppos 125 mg..............................Panadol Suppos 250 mg..............................Panadol

38.20 38.65

5 5

1% 1%

May-09 May-09

7.49 14.40

20 20

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 April 2009 (continued)

ROPINIROLE (new listing and HSS) Tab 0.25 mg ..................................Ropin 7.90 84 1% June-09 Requip Tab 1 mg .......................................Ropin 40.32 84 1% June-09 Requip Tab 2 mg .......................................Ropin 60.72 84 1% June-09 Requip Tab 5 mg .......................................Ropin 90.00 84 1% June-09 Requip Note – Requip tab 0.25mg, 1 mg, 2 mg and 5mg and Requip Starter pack and Follow-on pack will all be delisted 1 September 2009 VERAPAMIL (delisting) Tab 40 mg .....................................Verpamil 4.75 100

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A Acitretin ................................................. 19, 23, 27 Albay ................................................................. 29 Adefin XL ........................................................... 30 Alendronate sodium ..................................... 24, 25 Allerid C ............................................................. 30 Allopurinol.............................................. 17, 29, 39 Amikacin sulphate .............................................. 43 Amikin ............................................................... 43 Amlodipine......................................................... 30 Amoxil Paediatric Drops ............................... 31, 37 Amoxycillin .................................................. 31, 37 Amoxycillin clavulanate ................................ 16, 40 Anastrozole .................................................. 26, 30 Anusol ............................................................... 30 Apo-Allopurinol .................................................. 17 Apo-Doxazosin................................................... 39 APO-go .............................................................. 42 Apomine ...................................................... 15, 43 Apomorphine hydrochloride ................... 15, 42, 43 Aqueous ............................................................ 30 Aqueous cream ............................................ 31, 37 Arimidex ...................................................... 26, 30 Arrow-Citalopram ......................................... 31, 37 Arrow-Nifedipine XR ........................................... 30 Arrow-Simva ...................................................... 16 Artex .................................................................. 27 Aspec 300 ......................................................... 29 Aspirin ............................................................... 29 Atomoxetine hydrochloride ........................... 15, 43 Augmentin ......................................................... 40 Auranofin ..................................................... 24, 27 Azol ............................................................. 15, 43 B Baclofen ............................................................ 25 Bakels Gluten Free Health Bread Mix ................... 28 Bee venom allergy treatment .............................. 29 Bezafibrate ......................................................... 27 Bezalip Retard .................................................... 27 Bonjela .............................................................. 28 C Calcitonin........................................................... 25 Calcium ............................................................. 35 Calsource .......................................................... 35 Calvasc.............................................................. 30 Capadex............................................................. 29 Carbamazepine .................................................. 39 Carbohydrate supplement................................... 42 Celapram ..................................................... 31, 37 Cetirizine hydrochloride ...................................... 30 Choline salicylate with cetalkonium chloride........ 28 Cilazapril ...................................................... 16, 41 Cipflox ......................................................... 31, 37 Ciprofloxacin ................................................ 31, 37 Citalopram hydrobromide ............................. 31, 37 Citalopram-Rex ............................................ 31, 37 Clopine ........................................................ 17, 32 Clotrimaderm 2% ......................................... 29, 31 Clotrimazole ................................................. 29, 31 Clozapine ......................................... 15, 17, 32, 43 Clozaril .................................................. 15, 32, 43 Coal tar with salicylic acid and sulphur ............... 35 Coco-Scalp ........................................................ 35 Condoms ........................................................... 16 Coal tar .............................................................. 35 Crotamiton ......................................................... 39 D D-Penamine ....................................................... 24 Daktarin ................................................. 27, 28, 35 Danazol........................................................ 15, 43 Dantrium ............................................................ 25 Dantrolene sodium ............................................. 25 De-Worm ........................................................... 16 Dextropropoxyphene with paracetamol ............... 29 Diabetic enteral feed 1kcal/ml ............................. 41 Diazepam..................................................... 27, 43 Diclocil .............................................................. 41 Dicloxacillin........................................................ 41 Doxazosin mesylate ........................................... 39 Dr Reddy’s Omeprazole................................ 16, 43 Durex Extra Safe................................................. 16 Durex Select Flavours ......................................... 16 E Eloxatin .............................................................. 32 Ethambutol hydrochloride ................................... 27 Ethics Ibuprofen ................................................. 16 Ethinyloestradiol with gestodene ......................... 41 Ethinyloestradiol with levonorgestrel ................... 41 Eurax ................................................................. 39 F Fleet Glycerin Suppositories ............................... 40 Flucloxacillin sodium .......................................... 37 Flucloxin ............................................................ 37 Fluorouracil sodium............................................ 39 Food Thickener .................................................. 16 Fosamax ...................................................... 24, 25 Fosamax Plus .................................................... 24 G Gaviscon ........................................................... 28 Gaviscon Double Strength .................................. 28 Gemcitabine Ebewe...................................... 15, 43 Gemcitabine hydrochloride ........................... 15, 43 Glucose dehydrogenase ......................... 16, 34, 40 Gluten free bread mix ......................................... 28

Index

Pharmaceuticals and brands Gluten free flour ................................................. 28 Gluten free pasta .............................. 17, 33, 38, 40 Glycerol ............................................................. 40 Glyceryl trinitrate .......................................... 22, 36 H Heparinised saline .............................................. 40 Horleys Bread Mix .............................................. 28 Horleys Flour...................................................... 28 Hyalase.............................................................. 27 Hyalurodinase .................................................... 27 Hydrocortisone butyrate ..................................... 35 Hydrogen peroxide ............................................. 35 Hyoscine (scopolamine)..................................... 31 Hypam ............................................................... 29 Hypnovel ........................................................... 29 Hypromellose..................................................... 32 I I-Profen ............................................................. 40 Ibiamox........................................................ 31, 37 Ibuprofen ..................................................... 16, 40 Indomethacin ..................................................... 41 Inhibace ....................................................... 16, 41 Insulin aspart ..................................................... 27 Isotane 10.................................................... 18, 22 Isotane 20.................................................... 18, 22 Isotretinoin ................................................... 18, 22 K K-Thrombin........................................................ 40 Kenacomb ......................................................... 41 Kenacort-A......................................................... 41 Ketoconazole ..................................................... 27 Ketovite Liquid ................................................... 34 Ketovite Syrup.................................................... 34 L Labetalol ............................................................ 41 Lipex.................................................................. 40 Liquifilm Forte .................................................... 37 Liquifilm Tears ................................................... 37 Locoid Crelo ...................................................... 35 Loprofin ............................................................. 37 Losec .......................................................... 28, 30 Lycinate ............................................................. 22 M Mebendazole................................................ 16, 40 Menadione sodium bisulphite ............................. 40 Methopt ............................................................. 32 Metoclopramide hydrochloride with paracetamol 31 Magnesium hydroxide mixture ............................ 26 Mestinon............................................................ 31 Miacalcic ........................................................... 25 Miconazole ........................................................ 28 Miconazole nitrate ........................................ 27, 35 Midazolam ......................................................... 29 Minulet 28.......................................................... 41 Multivitamins ..................................................... 34 Myambutol......................................................... 27 Mylanta P .......................................................... 27 Myocrisin........................................................... 24 N Neotigason ............................................ 19, 23, 27 Nifedipine........................................................... 30 Nizoral ............................................................... 27 Norpress ............................................................ 38 Nortriptyline hydrochloride.................................. 38 NovoRapid ......................................................... 27 NovoRapidPenfill ................................................ 27 Nutraplus ........................................................... 30 NZB Low Gluten Bread Mix ................................. 28 O Octreotide (somatostatin analogue) .............. 29, 32 Oestradiol valerate.............................................. 39 Omeprazole...................................... 16, 28, 30, 38 Omeprazole (hss)............................................... 43 Omezol .............................................................. 38 Ondansetron ...................................................... 22 Optium............................................................... 34 Optium 5 second test ......................................... 16 Optium 10 second test ................................. 34, 40 Oral feed 1kcal/ml ........................................ 37, 40 Orgran ............................................. 17, 33, 38, 40 Oxaliplatin .......................................................... 32 P Pacifen .............................................................. 25 Paediatric oral feed 1.5kcal/ml............................ 39 Paediatric oral feed 1kcal/ml............................... 42 Pamidronate disodium ....................................... 25 Pamisol ............................................................. 25 Panadol ........................................... 28, 31, 39, 43 Pantocid I.V ....................................................... 16 Pantoprazole ...................................................... 16 Paracetamol..................................... 28, 31, 39, 43 Paramax ............................................................ 31 Parnate .............................................................. 17 Pediasure........................................................... 42 Pegasys............................................................. 19 Pegasys RBV Combination Pack .................. 19, 20 Pegatron Combination Therapy ........................... 21 Pegylated interferon alpha-2a ............................. 19 Pegylated interferon alpha-2b with ribavirin ......... 21 Penicillamine...................................................... 24 Phenyl free pasta ............................................... 37 Polycose............................................................ 42 Polytar Emollient ................................................ 35 Polyvinyl alcohol ................................................ 37

Index

Pharmaceuticals and brands Progout........................................................ 29, 39 Progynova ......................................................... 39 Protamine sulphate ............................................ 27 Pyridostigmine bromide...................................... 31 R Razene .............................................................. 30 Requip ......................................................... 22, 41 Requip Follow-On Pack ...................................... 22 Requip Follow-on Pack....................................... 41 Requip Starter Pack...................................... 22, 41 Resource Diabetic ........................................ 37, 40 Resource Diabetic TF RTH.................................. 41 Resource Just for Kids ....................................... 39 Resource Thicken Up ......................................... 16 Rheumacin ........................................................ 41 Ridaura ........................................................ 24, 27 Ropin ..................................................... 15, 22, 44 Ropinirole .......................................................... 44 Ropinirole hydrochloride......................... 15, 22, 41 S Sandostatin .................................................. 29, 32 Scopoderm TTS ................................................. 31 Simethicone ....................................................... 27 SimvaRex .......................................................... 40 Simvastatin .................................................. 16, 40 Sodium alginate ................................................. 28 Sodium aurothiomalate ...................................... 24 Stelazine ............................................................ 28 Stesolid ....................................................... 27, 43 Strattera ....................................................... 15, 43 Synermox .......................................................... 16 T Tar with cade oil................................................. 35 Tegretol ............................................................. 39 Trandate ............................................................ 41 Tranylcypromine sulphate .................................. 17 Triamcinolone acetonide .................................... 41 Triamcinolone acetonide with gramicidin, neomycin and nystatin .............................. 30, 41 Triazolam ........................................................... 29 Trifluoperazine hydrochloride .............................. 28 Trimipramine maleate ......................................... 30 Triphasil 28 ........................................................ 41 Tripress ............................................................. 30 U Urea................................................................... 30 V Verapamil .......................................................... 44 Verapamil hydrochloride ..................................... 37 Vermox ........................................................ 16, 40 Verpamil ...................................................... 37, 44 Viaderm KC........................................................ 30 W Wasp venom allergy treatment ........................... 29 Water ................................................................. 39 Z Zinc oxide .......................................................... 30 Zofran ................................................................ 22 Zofran Zydis ....................................................... 22

Pharmaceutical Management Agency Level 9, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 April 2009

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 April 2009 Cumulative for January, February, March and April 2009 Section H for April 2009 Contents Summary of PHARMAC decisions effective 1 April 2009 …. 3 Atomoxetine hydrochloride – new…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.